Recently, a promising strategy for enhancing the effectiveness of tumor immunotherapy has emerged through the combined application of IDO inhibition and immune checkpoint blockade, as reported in studies (Zamarin and Postow, 2015; Tierney et al., 2020). The gene discussed is IDO1; the disease is neoplasm.